Table 2 MRI evaluation of cartilage regeneration in osteoarthritis
Lead author (year) Cell type | MRI Protocol | Assessment | F/U (mo, y) | Cartilage pathology | Overall results of cell therapy | |
|---|---|---|---|---|---|---|
Study | Control | |||||
Zhang (2021) ADSVF | PDFS | Total cartilage volume (mm3) | Baseline | 16,467.89 ± 2739.13 | 15,718.20 ± 2071.90 | The defect size increased more in the control group. The SVF group had fewer patients experiencing progression |
5 y | 15,121.11 ± 3174.45 | 13,473.30 ± 2489.59 | ||||
Full-thickness defect | 5 y | Decrease: 3 (5.9%) No change: 44 (86.3%) | Decrease: 0 (0%) No change: 52 (81.3%) | |||
Zhang* (2021) ADSVF | PDFS and 3D-FS-SPGR | WORMS | Baseline | 64.28 ± 13.90 | 63.99 ± 13.38 | The study group showed significant improvement at 6 and 12 months, while the control group experienced significant deterioration at the same time points |
6 mo | 53.88 ± 12.61 | 72.16 ± 13.74 | ||||
12 mo | 48.17 ± 11.40 | 74.97 ± 12.80 | ||||
MOCART | 6 mo | 50.00(12.60) | 21.77 (13.34) | |||
12 mo | 59.81 (12.59) | 18.24 (9.48) | ||||
Garza (2020) ADSVF | PDFS | Cartilage thickness (change) | 6 mo | − 0.2 mm | 10.5 mm | Modified disease progression No difference No change after treatment |
12 mo | − 0.1 mm | 10.8 mm | ||||
Outerbridge grade (change) | 6 mo | 0 | 0 | |||
12 mo | 0 | 0 | ||||
Freitag (2019) ASC | PDFS | MOAKS | 12 mo | Improved: 1/19 (5.3%) No change: 14/19 (73.7%) Progression: 4/19 (21.0%) | Improved: 0/9 (0%) No change: 3/9 (33%) Progression:6/9 (67%) | Tended to be better in the ASC group than in the control group, but not significant |
Hong (2019) ADSVF | PDFS | WORMS | Baseline | 71.31 ± 24.2 | 69.81 ± 18.05 | The study group showed significant improvement at 6 and 12 months, while the control group experienced significant deterioration at the same time points |
6 mo | 59.93 ± 24.89 | 82.62 ± 12.66 | ||||
12 mo | 55.87 ± 21.95 | 85.31 ± 14.65 | ||||
MOCART | 6 mo | 54.06 (11.58) | 19.38 (9.64) | |||
12 mo | 62.81 (8.16) | 19.06 (7.79) | ||||
Lu (2019) ASC | PDFS | Cartilage volume (change) | 6 mo | Significantly increased in the right knee | Significantly decreased in the left tibia | Significant difference in the left tibia and right femur (ASC treatment was better than HA) |
12 mo | Significantly increased in both femurs | No significant change | Significant difference in both femurs ASC treatment was better than HA | |||
Lee (2019) ASC | PDFS | Cartilage defect size (mm2) | Baseline | 312.47 ± 270.97 | 320.02 ± 273.02 | No significant change in the ASC group; significant increase in defect size in the control group. ASC treatment better than placebo |
6 mo | 314.86 ± 267.33 | 355.61 ± 258.54 | ||||
Gap | + 2.4 ± 14.5 | + 35.6 ± 58.8 | ||||